← Back to Search

Unknown

VX-548 for Pain

Phase 1
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests a new drug called VX-548 in healthy people to see how it behaves in their bodies and if it is safe. Researchers want to understand how the drug moves through and affects the body before using it on patients with specific conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: VX-548Experimental Treatment1 Intervention
Participants will be randomized to receive a single dose of VX-548 in 1 of 6 treatment sequences with 3 dosing periods to assess different fed conditions and timing of meal administration on the PK of VX 548. There will be a 14 day washout period between each dosing period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
VX-548
2022
Completed Phase 3
~3580

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
251 Previous Clinical Trials
32,791 Total Patients Enrolled
19 Trials studying Pain
1,258 Patients Enrolled for Pain

Media Library

VX-548 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT05851157 — Phase 1
Pain Research Study Groups: VX-548
Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05851157 — Phase 1
VX-548 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05851157 — Phase 1
~31 spots leftby Sep 2025